25 stories across all digests
The FLOW trial showed semaglutide reduced major kidney events by 24%, and retatrutide demonstrated up to 28.7% weight loss in TRIUMPH-4. The full pipeline including CagriSema, MariTide, and survodutide was presented.
Retatrutide met its primary endpoint of superior A1C reduction and all key secondary endpoints at 40 weeks compared with placebo in type 2 diabetes patients, also demonstrating significant weight loss.
The ACHIEVE-3 trial in The Lancet showed Eli Lilly's Foundayo (orforglipron) superior on HbA1c, while Novo Nordisk's oral Wegovy may have an edge in weight-loss efficacy.
Novo Nordisk's long-acting amylin analog produced significant weight loss as standalone treatment in a 68-week double-blind trial, strengthening its profile ahead of the CagriSema FDA decision.
Phase IIIb results show investigational 7.2 mg semaglutide dose produced 21% mean weight loss in adults with obesity without diabetes, with a tolerable safety profile.
The 25-mg oral semaglutide formulation broadens GLP-1 access for chronic weight management, with pharmacists playing a key role in patient counseling and adherence support.
Orforglipron (Foundayo) is the first GLP-1 pill that can be taken at any time without food or water restrictions, a major differentiator from oral semaglutide which requires morning dosing on an empty stomach.
Eli Lilly's triple agonist (GIP/GLP-1/glucagon) retatrutide met its primary A1C reduction endpoint and all key secondary endpoints at 40 weeks in the TRANSCEND-T2D-1 trial.
Managed Healthcare Executive compares Foundayo (orforglipron) vs oral Wegovy (semaglutide). ACHIEVE-3 trial data showed Foundayo superior on HbA1c, but oral Wegovy may edge ahead on weight loss.
Eli Lilly's triple GLP-1/GIP/glucagon receptor agonist retatrutide demonstrated up to 28.7% weight loss along with significant knee pain reductions in obesity patients with osteoarthritis. Seven additional Phase 3 trials expected to report throughout 2026.
The ATTAIN-MAINTAIN trial demonstrated that patients switching from injectable semaglutide or tirzepatide to oral orforglipron maintained their weight loss.
At APhA2026, semaglutide's FLOW trial showed 24% reduction in major kidney events in CKD patients, while tirzepatide's SURMOUNT-OSA trial demonstrated dramatic reductions in sleep apnea severity.
Eli Lilly's oral GLP-1 drug orforglipron is among the most consequential FDA decisions in Q2 2026. Analysts expect it to help Lilly's tirzepatide franchise exceed $100 billion in peak revenue.
Oral peptide icotrokinra delivered complete skin clearance through week 52 with a strong safety profile in the ICONIC-ADVANCE trials, presented at the American Academy of Dermatology meeting.
Patients switching from dulaglutide to tirzepatide reported greater improvement in weight-related self-perception at week 40, highlighting benefits beyond glycemic control.
Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.
Novo Nordisk's amylin analog peptide showed significant weight loss as standalone treatment in Phase 3 trial data, positioning it as a new pillar in peptide-based obesity treatment.
Pharmacy Times covers orforglipron's ability to cut A1C and drive meaningful weight loss with easier dosing than injections, potentially reshaping the GLP-1 treatment landscape.